As of 2025-05-25, the EV/EBITDA ratio of Ocumension Therapeutics (1477.HK) is -32.92. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. 1477.HK's latest enterprise value is 5,059.89 mil HKD. 1477.HK's TTM EBITDA according to its financial statements is -153.70 mil HKD. Dividing these 2 quantities gives us the above 1477.HK EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 19.4x - 27.2x | 22.3x |
| Forward P/E multiples | 9.8x - 12.5x | 11.6x |
| Fair Price | (3.01) - 12.79 | 4.16 |
| Upside | -141.7% - 77.4% | -42.3% |
| Date | EV/EBITDA |
| 2025-05-23 | -269.44 |
| 2025-05-22 | -288.08 |
| 2025-05-21 | -254.23 |
| 2025-05-20 | -254.99 |
| 2025-05-19 | -225.32 |
| 2025-05-16 | -199.07 |
| 2025-05-15 | -196.02 |
| 2025-05-14 | -196.40 |
| 2025-05-13 | -193.36 |
| 2025-05-12 | -192.98 |
| 2025-05-09 | -196.40 |
| 2025-05-08 | -193.74 |
| 2025-05-07 | -196.78 |
| 2025-05-06 | -199.83 |
| 2025-05-02 | -202.11 |
| 2025-04-30 | -201.35 |
| 2025-04-29 | -201.35 |
| 2025-04-28 | -201.35 |
| 2025-04-25 | -205.15 |
| 2025-04-24 | -205.53 |
| 2025-04-23 | -202.49 |
| 2025-04-22 | -186.13 |
| 2025-04-17 | -176.62 |
| 2025-04-16 | -177.00 |
| 2025-04-15 | -184.61 |
| 2025-04-14 | -183.85 |
| 2025-04-11 | -176.62 |
| 2025-04-10 | -172.82 |
| 2025-04-09 | -156.84 |
| 2025-04-08 | -158.74 |
| 2025-04-07 | -159.12 |
| 2025-04-03 | -192.60 |
| 2025-04-02 | -197.16 |
| 2025-04-01 | -198.69 |
| 2025-03-31 | -187.65 |
| 2025-03-28 | -184.61 |
| 2025-03-27 | -182.33 |
| 2025-03-26 | -180.05 |
| 2025-03-25 | -181.19 |
| 2025-03-24 | -188.80 |
| 2025-03-21 | -186.89 |
| 2025-03-20 | -196.78 |
| 2025-03-19 | -190.70 |
| 2025-03-18 | -185.75 |
| 2025-03-17 | -182.33 |
| 2025-03-14 | -178.14 |
| 2025-03-13 | -169.39 |
| 2025-03-12 | -171.30 |
| 2025-03-11 | -177.76 |
| 2025-03-10 | -175.86 |